Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice

Journal of Medical Microbiology

Volumn 47, Issue 4, 1998, Pages 295-301

  Matsumoto, T ^b   Tateda, K ^b   Miyazaki, S ^b   Furuya, N ^b   Ohno, A ^b   Ishii, Y ^b   Hirakata, Y ^a   Yamaguchi, K ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PROTEINASE; CYCLOPHOSPHAMIDE; ELASTASE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SURVIVAL RATE; VACCINATION;

EID: 0031885114     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-47-4-295     Document Type: Article

References (25)

1. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5: 629-638.
2. Dick JD, Shull V, Karp JE, Valentine J. Bacterial and host factors affecting Pseudomonas aeruginosa colonization versus bacteremia in granulocytopenic patients. Eur J Cancer Clin Oncol 1988; 24 Suppl 1: S47 S54.
3. Young LS, Stevens P, Kaijser B. Gram-negative pathogens in septicaemic infections. Scand J Infect Dis 1982; Suppl 31: 78 94.
4. Tamura M, Matsumoto M, Yoshino T et al. Effects of recombinant human granulocyte colony-stimulating factor on the mice receiving bone marrow transplantation following lethal irradiation: acceleration of recovery of the peripheral blood neutrophils and potentiation of anti-Pseudomonas resistance. Exp Hematol 1991; 19: 18 23.
5. Alpert SE, Pennington JE, Colten HR. Synthesis of complement by guinea pig bronchoalveolar macrophages. Effect of acute and chronic infection with Pseudomonas aeruginosa. Am Rev Respir Dis 1984; 129: 66-71.
6. Richardson JD, DeCamp MM, Garrison RN, Fry DE. Pulmonary infection complicating intra-abdominal sepsis: clinical and experimental observations. Ann Surg 1982; 195: 732-738.
7. Tancrède CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 1985; 152: 99-103.
8. Berg RD, Garlington AW. Translocation of Escherichia coli from the gastrointestinal tract to the niesenteric lymph nodes in gnotobiotic mice receiving Escherichia coli vaccines before colonization. Infect Immun 1980; 30: 894-898.
9. Deitch EA, Winterton J, Berg T. Thermal injury promotes bacterial translocation from the gastrointestinal tract in mice with impaired T-cell-mediated immunity. Arch Surg 1986; 121: 97 101.
10. Hirakata Y, Kaku M, Tomono K et al. Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrob Agents Chemother 1992; 36: 1198 1203.
11. Pennington JE, Ehrie MG, Hickey WF. Host defense mechanisms against pneumonia due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6 Suppl 3: S657 S666.
12. Wassermann D, Schlotterer M, Paul P, Rieu M. Systematic utilization of an antipseudomonas aeruginosa vaccine in a severe burn unit. Scand J Plast Reconstr Surg 1979; 13: 81 84.
13. Stanislavsky ES, Joo I. Mashilova GM et al. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies. Vaccine 1985; 3: 128 136.
14. McManus AT. Examination of neutrophil function in a rat model of decreased host resistance following burn trauma. Rev Infect Dis 1983; 1 Suppl 5: S898 S907.
15. Hirakata Y, Tomono K, Tateda K et al. Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia. Infect Immun 1991; 59: 289 294.
16. Cryz, SJ, Furer E, Que JU Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun 1991; 59: 45-50.
17. Matsumoto T, Tateda K, Miyazaki S et al. lmmunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1997; 41: 308-313.
18. Matsumoto T, Tateda K, Miyazaki S et al. Adverse effects of tumor necrosis factor in cyclophosphamide-treated mice subjected to gut-derived Pseudomonas aeruginosa sepsis. Cytokine 1997 (in press).
19. Woods DE, Vasil ML. Pathogenesis of Pseudomonas aeruginosa infections. In: Baltch AL, Smith RP (eds) Pseudomonas aeruginosa infections and treatment. New York, Marcel Dekker. 1993: 21-50.
20. Goto S. Recent progress in the identification of pathogenic factors of Pseudomonas aeruginosa. J Infect Chemother 1996; 2: 111-116.
21. Fomsgaard A, Holder IA. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS 1993; 101: 229-234.
22. Jones RJ, Roe EA, Gupta JL. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet 1979; 2: 977-982.
23. Cryz SJ, Furer E, Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun 1983; 39: 1067-1071.
24. Cryz SJ, Furer E, Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun 1984; 43: 795-799.
25. Cryz SJ, Sadoff JC, Furer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog 1989; 6: 75-80.